Please ensure Javascript is enabled for purposes of website accessibility

Amarin Given 3-Year Exclusivity for Vascepa

By Eric Volkman – Feb 21, 2014 at 10:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amarin is granted exclusivity from the FDA, but was hoping for a longer term.

Amarin (AMRN -4.27%) has received an important approval from the Food and Drug Administration, but the company is not necessarily happy about it. The FDA  awarded the firm three years of marketing exclusivity for Vascepa capsules. That approval expires in July 2015, as it is backdated to the original approval granted Vascepa for the treatment of severe hypertriglyceridemia. This disorder is the overabundance of triglycerides, a fatty molecule, which puts the afflicted party at risk of pancreatitis.

In the press release announcing the news, Amarin made little attempt to hide its dissatisfaction with the term of the approval, hinting at a potential effort to lengthen it. The firm quoted its CEO John Thero as saying that, "Amarin is reviewing the FDA's reasoning for granting Vascepa three-year, rather than five-year, exclusivity, and evaluating whether to challenge the decision."

Eric Volkman has no position in Amarin. Nor does The Motley Fool. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Stock Quote
Amarin
AMRN
$1.12 (-4.27%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.